Funding for this research was provided by:
National Cancer Institute (R21 CA197752)
Center for Individualized Medicine, Mayo Clinic
Received: 19 November 2018
Accepted: 14 February 2019
First Online: 8 March 2019
Ethics approval and consent to participate
: This study was conducted under approval of our Institutional Review Board and was in compliance with the US Health Insurance Portability and Accountability Act. Informed written consent was obtained from all participants.
: Not applicable
: CH and MO receive royalties for licensed technologies per agreement between Mayo Clinic and CMR Naviscan, a manufacturer of molecular breast imaging systems. All other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.